“Z\u0101\u013cu biznes\u0101 j\u0101dom\u0101 t\u0101lu uz priek\u0161u”
“Latvijas z\u0101\u013cu tirgus Grindeka jaudai ir par mazu, t\u0101d\u0113\u013c no visas sara\u017eot\u0101s produkcijas Latvij\u0101 p\u0101rdodam ne vair\u0101k, k\u0101 \u010detrus procentus un 96% eksport\u0113jam. Latvijas m\u0113rogus jau sen esam p\u0101raugu\u0161i,” uzsver a\/s Grindeks valdes priek\u0161s\u0113d\u0113t\u0101js J\u0101nis Romanovskis. Sarun\u0101 ar vi\u0146u skaidroju, kas ir \u0161\u0101 uz\u0146\u0113muma veiksmes st\u0101sta pamat\u0101.<\/p>\n\n\n\n
\u2013 K\u0101ds ir Grindeks v\u0113st\u012bjums, ar ko ejat citu valstu tirgos, ko dar\u0101t, lai iekarotu to z\u0101\u013cu tirgu?<\/strong><\/p>\n\n\n\n \u2013 M\u016bsu arguments: Grindeks z\u0101les ir dro\u0161as, kvalitat\u012bvas un ra\u017eotas Eiropas Savien\u012bb\u0101. Kad esam veiku\u0161i z\u0101\u013cu re\u0123istr\u0101cijas procesu, kas da\u017e\u0101d\u0101s valst\u012bs ir at\u0161\u0137ir\u012bgs un var ilgt no devi\u0146iem m\u0113ne\u0161iem l\u012bdz pat trim gadiem, s\u0101kam c\u012b\u0146u par tirgus da\u013cu. Tas noz\u012bm\u0113, ka m\u016bsu pied\u0101v\u0101taj\u0101m z\u0101l\u0113m, piem\u0113ram, patentbr\u012bvajiem medikamentiem, j\u0101b\u016bt vai nu lab\u0101k\u0101m, l\u0113t\u0101k\u0101m, pievilc\u012bg\u0101k\u0101 iepakojum\u0101, vai ar\u012b kampa\u0146ai j\u0101b\u016bt atrakt\u012bv\u0101kai. Un te nu izpau\u017eas m\u016bsu rado\u0161\u0101 doma, m\u016bsu intelektu\u0101l\u0101 pievienot\u0101 v\u0113rt\u012bba, lai par\u0101d\u012btu, k\u0101p\u0113c pirkt Grindeks ra\u017eot\u0101s z\u0101les. V\u0113l grib\u0113tu uzsv\u0113rt, ka Grindeks ir unik\u0101ls, vertik\u0101li integr\u0113ts farm\u0101cijas uz\u0146\u0113mums, proti, m\u0113s pa\u0161u sp\u0113kiem realiz\u0113jam gandr\u012bz visus z\u0101\u013cu ra\u017eo\u0161anas procesus \u2013 no p\u0113tniecisk\u0101s izstr\u0101des, substan\u010du un gatavo z\u0101\u013cu ra\u017eo\u0161anas l\u012bdz p\u0101rdo\u0161anai. Ra\u017eo\u0161ana notiek p\u0113c farm\u0101cijas biznes\u0101 tik svar\u012bgajiem GMP jeb Labas ra\u017eo\u0161anas prakses standartiem.<\/p>\n\n\n\n \u2013 Biju\u0161ais a\/s Grindeks valdes priek\u0161s\u0113d\u0113t\u0101js Valdis J\u0101kobsons reiz k\u0101d\u0101 intervij\u0101 atzinis, ka z\u0101\u013cu ra\u017eo\u0161ana ir izdev\u012bgs bizness, jo cilv\u0113ks ir t\u0101 rad\u012bts, ka vi\u0146\u0161 slimo. J\u016bsu uz\u0146\u0113muma m\u0101jaslap\u0101 publiskotie dati liecina, ka Grindeks pe\u013c\u0146a 2008. gad\u0101 pieaugusi par 26,8% sal\u012bdzin\u0101jum\u0101 ar 2007. gadu. Vai tie\u0161\u0101m cilv\u0113ki s\u0101ku\u0161i vair\u0101k slimot?<\/strong><\/p>\n\n\n\n \u2013 N\u0113, dom\u0101ju, iemesli ir citi. Pag\u0101ju\u0161aj\u0101 gad\u0101 m\u016bsu uz\u0146\u0113muma apgroz\u012bjums bija vair\u0101k nek\u0101 62 miljoni latu, pe\u013c\u0146a p\u0113c nodok\u013cu samaksas \u2013 devi\u0146i miljoni latu. P\u0113d\u0113jie se\u0161i gadi, kop\u0161 nomain\u012bj\u0101s akcion\u0101ri, ir Grindeks izaugsmes laiks, jo akcion\u0101ri izv\u0113l\u0113j\u0101s nevis pa\u0146emt naudu dividen\u017eu veid\u0101, bet gan ieguld\u012bt to uz\u0146\u0113muma izaugsm\u0113 un att\u012bst\u012bb\u0101. Esam at\u013c\u0101vu\u0161ies invest\u0113t visu pe\u013c\u0146u, un l\u012bdz ar to esam gan jaunus tirgus apguvu\u0161i, gan izveidoju\u0161i jaunu akt\u012bvo farmaceitisko vielu anal\u012btisk\u0101s m\u0113rogo\u0161anas laboratoriju, gatavo z\u0101\u013cu formu ra\u017eotni un uzst\u0101d\u012bju\u0161i jaunas r\u016bpniecisko notek\u016bde\u0146u att\u012br\u012b\u0161anas iek\u0101rtas. Piem\u0113ram, jaunu z\u0101\u013cu izstr\u0101dei katru gadu t\u0113r\u0113jam 10% no uz\u0146\u0113muma apgroz\u012bjuma. Z\u0101\u013cu biznes\u0101 j\u0101dom\u0101 t\u0101lu uz priek\u0161u, jo neko nevar izdar\u012bt \u0101tri.<\/p>\n\n\n\n \u2013 Tom\u0113r Grindeks t\u0101pat k\u0101 jebkura farm\u0101cijas uz\u0146\u0113muma liel\u0101kais lepnums ir ori\u0123in\u0101lprodukti, jo cit\u0101s valst\u012bs tiem tikpat k\u0101 nav konkurentu, p\u0113c tiem ir liels piepras\u012bjums, un l\u012bdz ar to tie ienes labu pe\u013c\u0146u. Ori\u0123in\u0101lprodukts mildron\u0101ts ne vienu gadu vien atz\u012bts par Latvijas eksportsp\u0113j\u012bg\u0101ko produktu<\/strong>.<\/p>\n\n\n\n \u2013 J\u0101, mildron\u0101ts ir m\u016bsu pe\u013c\u0146as avots un lepnums. \u0160is Latvijas zin\u0101tnieku izgudrotais sirds un asinsvadu grupas medikaments komp\u0101nijas apgroz\u012bjum\u0101 veido vair\u0101k nek\u0101 70%, t\u0101d\u0113\u013c tas ir \u013coti svar\u012bgs uz\u0146\u0113mumam. P\u0113d\u0113jos asto\u0146os gados esam m\u0101c\u0113ju\u0161i palielin\u0101t mildron\u0101ta lietot\u0101ju loku un uztic\u012bbu produktam. T\u0101, piem\u0113ram, 2007. gad\u0101 98% no mildron\u0101ta apgroz\u012bjuma kopum\u0101 veidoja eksports. Pag\u0101ju\u0161aj\u0101 gad\u0101 gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjoms Krievij\u0101 sal\u012bdzin\u0101jum\u0101 ar 2007. gadu pieauga par 22,1 procentu. Piepras\u012bt\u0101kais Grindeka medikaments Krievij\u0101 joproj\u0101m ir mildron\u0101ts. Pag\u0101ju\u0161aj\u0101 gad\u0101 p\u0113c p\u0101rdo\u0161anas apjoma mildron\u0101ts Krievij\u0101 ierindoj\u0101s 15. viet\u0101. B\u016btiski \u0161o rezult\u0101tu ietekm\u0113ja Grindeks nosl\u0113gtais l\u012bgums ar Krievijas farm\u0101cijas uz\u0146\u0113mumu \u201cFarmstandart\u201d, kas k\u013cuva par mildron\u0101ta ekskluz\u012bvo izplat\u012bt\u0101ju \u0161aj\u0101 valst\u012b.<\/p>\n\n\n\n \u2013 Vai mildron\u0101ta lab\u0101 slava Krievijas tirg\u016b nav cietusi p\u0113c \u013coti nepat\u012bkam\u0101 gad\u012bjum\u0101, kad cits j\u016bsu sadarb\u012bbas partneris Krievij\u0101 farm\u0101cijas uz\u0146\u0113mums \u201cFarmFirma \u201cSoteks\u201d\u201d k\u013c\u016bdaini ar mildron\u0101ta eti\u0137eti nomar\u0137\u0113ja citas z\u0101les?<\/strong><\/p>\n\n\n\n \u2013 V\u0113los uzsv\u0113rt, ka p\u0113c min\u0113t\u0101s ra\u017eo\u0161anas k\u013c\u016bdas uz\u0146\u0113mum\u0101 \u201cFarmFirma \u201cSoteks\u201d\u201d nekav\u0113joties taj\u0101 p\u0101rtrauc\u0101m mildron\u0101ta ampulu ra\u017eo\u0161anu un nodro\u0161in\u0101j\u0101m, ka Krievija un citas NVS valstis sa\u0146em ES valstu \u2013 Lietuvas, Polijas vai Slov\u0101kijas \u2013 farm\u0101cijas uz\u0146\u0113mumos ra\u017eot\u0101s mildron\u0101ta injekcijas. M\u0113s Krievij\u0101 akt\u012bvi skaidroj\u0101m, ka notiku\u0161ais nav saist\u012bts ar mildron\u0101tu, kas ir dro\u0161as, stabilas z\u0101les. Papildu unik\u0101laj\u0101m prepar\u0101ta iedarb\u012bbas \u012bpa\u0161\u012bb\u0101m tam ir \u013coti maz blakuspar\u0101d\u012bbu. Liel\u0101 m\u0113r\u0101 tas ir t\u0101p\u0113c, ka esam pan\u0101ku\u0161i, ka piemais\u012bjumu saturs, kur\u0161 visai bie\u017ei izraisa blakuspar\u0101d\u012bbas, ir 50 rei\u017eu maz\u0101ks, nek\u0101 noteikts z\u0101\u013cu uzraudz\u012bbas instit\u016bciju normat\u012bvajos aktos. Dom\u0101ju, ka \u0161\u012b m\u016bsu v\u0113sts non\u0101ca l\u012bdz liel\u0101kajai da\u013cai Krievijas iedz\u012bvot\u0101ju. Protams, no mums tas pras\u012bja laika, nervu, darba un l\u012bdzek\u013cu ieguld\u012bjumu skaidrojo\u0161aj\u0101 kampa\u0146\u0101.<\/p>\n\n\n\n \u2013 Mildron\u0101ts gan nav vien\u012bgais Grindeka medikaments, un ar\u012b valstis, uz kur\u0101m eksport\u0113jat savu produkciju, neaprobe\u017eojas tikai ar Krieviju, Ukrainu, Kazahst\u0101nu un Baltkrieviju.<\/strong><\/p>\n\n\n\n \u2013 Protams, m\u0113s tirgojam ar\u012b citus medikamentus, un m\u016bsu produktu grozs pak\u0101peniski pieaug. Kopum\u0101 katru gadu uz\u0146\u0113mums ievie\u0161 vair\u0101k nek\u0101 \u010detrus jaunus patentbr\u012bvus medikamentus. Vispirms t\u0101s piere\u0123istr\u0113jam Latvij\u0101, tad cit\u0101s valst\u012bs. Pavisam uz\u0146\u0113muma produkciju eksport\u0113jam uz vair\u0101k nek\u0101 40 valst\u012bm, un tas veido gandr\u012bz 96 procentus no kop\u0113j\u0101 apgroz\u012bjuma. Galvenie noieta tirgi bez jau min\u0113tajiem ir ar\u012b Baltijas valstis, Jap\u0101na un ASV. Piem\u0113ram, uz Jap\u0101nu jau vair\u0101k nek\u0101 30 gadu tirgojam pretv\u0113\u017ea l\u012bdzek\u013ca ftorafura \u2013 m\u016bsu otra ori\u0123in\u0101l\u0101 prepar\u0101ta \u2013 darb\u012bgo vielu, bet gatavo z\u0101\u013cu formu \u2013 400 mg kapsulas \u2013 p\u0101rdodam Jap\u0101nas un vair\u0101kos Eiropas valstu z\u0101\u013cu tirgos. Lai papla\u0161in\u0101tu jau eso\u0161o tirgu, veicam ar\u012b citu medikamentu re\u0123istr\u0101ciju, piem\u0113ram, Turcij\u0101. Jaunu tirgu ieg\u016b\u0161ana ir viens no veidiem, k\u0101 m\u016bsu uz\u0146\u0113mumam iesp\u0113jams att\u012bst\u012bties.<\/p>\n\n\n\n \u2013 Viesojoties Latvij\u0101, Lietuvas seima Vesel\u012bbas padomes priek\u0161s\u0113d\u0113t\u0101js Jozs Pund\u017eus izteicies, ka Grindeks patentbr\u012bvo z\u0101\u013cu ra\u017eo\u0161an\u0101 p\u0101rsp\u0113jis Lietuvas farm\u0101cijas uz\u0146\u0113mumu \u201cSanitas\u201d, kas ar\u012b darbojas \u0161aj\u0101 jom\u0101.<\/strong><\/p>\n\n\n\n \u2013 Br\u012bd\u012b, kad beidzas ori\u0123in\u0101lz\u0101\u013cu patenta aizsardz\u012bba, visas liel\u0101s komp\u0101nijas cen\u0161as piev\u0113rsties to ra\u017eo\u0161anai, un m\u0113s neesam iz\u0146\u0113mums. Pa\u0161laik Grindeks str\u0101d\u0101 pie 30 da\u017e\u0101du nosaukumu patentbr\u012bvaj\u0101m z\u0101l\u0113m. \u0160eit uz vietas ra\u017eojam \u0161o medikamentu gatav\u0101s formas \u2013 kapsulas, tabletes, s\u012brupus, bet ampulas p\u0113c komplektra\u017eo\u0161anas l\u012bgumiem ra\u017eojam Polij\u0101, Lietuv\u0101 un Slov\u0101kij\u0101. Pl\u0101nojam katru gadu ieviest \u010detrus l\u012bdz se\u0161us jaunus patentbr\u012bvus produktus tirg\u016b.<\/p>\n\n\n\n Strauji aug ar\u012b akt\u012bvo farmaceitisko vielu ra\u017eo\u0161ana, t\u0101, piem\u0113ram, 2009. gada pirmaj\u0101 ceturksn\u012b to eksports sasniedza 1,1 miljonu latu. Ar da\u017e\u0101m farmaceitiski akt\u012bvaj\u0101m viel\u0101m, piem\u0113ram, zopiklonu un oksitoc\u012bnu, nodro\u0161in\u0101m 30% pasaules tirg\u016b, bet ar vair\u0101k\u0101m veterin\u0101ro z\u0101\u013cu substanc\u0113m \u2013 25% ES valstu tirg\u016b. Kopum\u0101 ra\u017eojam 14 substances, bet t\u0101di produkti, kur pa\u0161i izgatavojam gan substanci, gan p\u0113c tam gatavo produktu, jau ir se\u0161i. \u0160obr\u012bd \u012bpa\u0161u uzman\u012bbu piev\u0113r\u0161am ar\u012b akt\u012bvo vielu p\u0113tniec\u012bbai, jo racion\u0101l\u0101ka ra\u017eo\u0161anas tehnolo\u0123ija vai main\u012bta procesa sec\u012bba un citi jaunievedumi ra\u017eo\u0161anas procesu padara \u0101tr\u0101ku vai l\u0113t\u0101ku.<\/p>\n\n\n\n \u2013 Vai z\u0101\u013cu ra\u017eo\u0161an\u0101 rea\u0123\u0113jat ar\u012b uz kr\u012bzes d\u0113\u013c radu\u0161os pieaugo\u0161o piepras\u012bjumu p\u0113c t\u0101 saucamaj\u0101m nervus nomierino\u0161aj\u0101m z\u0101l\u0113m?<\/strong><\/p>\n\n\n\n \u2013 Grindeks specializ\u0113jas sirds un asinsvadu, terapeitisko pretv\u0113\u017ea medikamentu un centr\u0101lo nervu sist\u0113mu ietekm\u0113jo\u0161o l\u012bdzek\u013cu ra\u017eo\u0161an\u0101. T\u0101d\u0113\u013c m\u016bsu portfel\u012b ir k\u0101das 12 \u201cnervus nomierino\u0161as\u201d z\u0101les, un piepras\u012bjums aug tie\u0161i \u0161aj\u0101 produktu grup\u0101. Interesanti, ka valst\u012bs, kuras sk\u0101rusi kr\u012bze, \u0161o l\u012bdzek\u013cu pat\u0113ri\u0146\u0161 ir \u013coti at\u0161\u0137ir\u012bgs, piem\u0113ram, Latvij\u0101 starp m\u016bsu desmit p\u0101rdot\u0101kajiem produktiem pieci ir no \u0161\u012bs z\u0101\u013cu grupas. Ta\u010du cit\u0101s valst\u012bs saka \u2013 priek\u0161 kam mums nomierino\u0161\u0101s z\u0101les, ja ir v\u012bns. T\u0101, piem\u0113ram, Gruzij\u0101, m\u016bsu desmit p\u0101rdot\u0101ko z\u0101\u013cu vid\u016b nav neviena nomierino\u0161\u0101 l\u012bdzek\u013ca. Vi\u0146iem ir piln\u012bgi cita mentalit\u0101te, citas trad\u012bcijas, un l\u012bdz ar to piepras\u012bjums valst\u012bs p\u0113c viena un t\u0101 pa\u0161a produkta ir apbr\u012bnojami da\u017e\u0101ds. M\u0113s pat pa\u0161i da\u017ereiz nevaram saprast, k\u0101p\u0113c vien\u0101 valst\u012b produkts tiek realiz\u0113ts labi, bet kaimi\u0146valst\u012b nav iecien\u012bts.<\/p>\n\n\n\n Kaut ar\u012b kr\u012bze ietekm\u0113jusi z\u0101\u013cu tirgu, kopum\u0101 \u0161\u0101 gada pirmaj\u0101 ceturksn\u012b esam str\u0101d\u0101ju\u0161i ar pe\u013c\u0146u, kas gan ir daudz maz\u0101ka nek\u0101 pirms gada taj\u0101 pa\u0161\u0101 ceturksn\u012b. Tom\u0113r optimismu nezaud\u0113jam un m\u0113r\u0137tiec\u012bgi darbosimies, lai papla\u0161in\u0101tu z\u0101\u013cu tirgus p\u0101rkl\u0101jumu.<\/p>\n","protected":false},"excerpt":{"rendered":" “Z\u0101\u013cu biznes\u0101 j\u0101dom\u0101 t\u0101lu uz priek\u0161u”“Latvijas z\u0101\u013cu tirgus Grindeka jaudai ir par mazu, t\u0101d\u0113\u013c no visas sara\u017eot\u0101s produkcijas Latvij\u0101 p\u0101rdodam ne vair\u0101k, k\u0101 \u010detrus procentus…<\/p>\n","protected":false},"author":3,"featured_media":6601,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-624","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-jaunums"],"acf":[],"_links":{"self":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/624","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/comments?post=624"}],"version-history":[{"count":0,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/624\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media\/6601"}],"wp:attachment":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media?parent=624"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/categories?post=624"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/tags?post=624"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}